IS2533B - (S)-2-N-própýlamínó-5-hýdroxýetralín sem D3-gerandefni - Google Patents

(S)-2-N-própýlamínó-5-hýdroxýetralín sem D3-gerandefni

Info

Publication number
IS2533B
IS2533B IS8505A IS8505A IS2533B IS 2533 B IS2533 B IS 2533B IS 8505 A IS8505 A IS 8505A IS 8505 A IS8505 A IS 8505A IS 2533 B IS2533 B IS 2533B
Authority
IS
Iceland
Prior art keywords
propylamino
agonist
hydroxyetraline
hydroxytetralin
dopa
Prior art date
Application number
IS8505A
Other languages
English (en)
Other versions
IS8505A (is
Inventor
Dieter Scheller
Klaus Hansen
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of IS8505A publication Critical patent/IS8505A/is
Publication of IS2533B publication Critical patent/IS2533B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
IS8505A 2003-12-18 2006-06-12 (S)-2-N-própýlamínó-5-hýdroxýetralín sem D3-gerandefni IS2533B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10359528A DE10359528A1 (de) 2003-12-18 2003-12-18 (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
PCT/EP2004/014143 WO2005058296A1 (de) 2003-12-18 2004-12-13 (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum

Publications (2)

Publication Number Publication Date
IS8505A IS8505A (is) 2006-06-12
IS2533B true IS2533B (is) 2009-07-15

Family

ID=34683532

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8505A IS2533B (is) 2003-12-18 2006-06-12 (S)-2-N-própýlamínó-5-hýdroxýetralín sem D3-gerandefni

Country Status (22)

Country Link
US (2) US8609641B2 (is)
EP (1) EP1694318B1 (is)
JP (1) JP5253737B2 (is)
KR (1) KR101083568B1 (is)
CN (1) CN1929829B (is)
AT (1) ATE356621T1 (is)
AU (1) AU2004298341B2 (is)
BR (1) BRPI0417739A (is)
CA (1) CA2547820C (is)
CY (1) CY1106589T1 (is)
DE (2) DE10359528A1 (is)
DK (1) DK1694318T3 (is)
ES (1) ES2282923T3 (is)
HK (1) HK1094421A1 (is)
HR (1) HRP20070175T3 (is)
IS (1) IS2533B (is)
MX (1) MXPA06006696A (is)
PL (1) PL1694318T3 (is)
PT (1) PT1694318E (is)
RS (1) RS50536B (is)
SI (1) SI1694318T1 (is)
WO (1) WO2005058296A1 (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
CN101970422B (zh) * 2007-11-28 2014-10-22 Ucb制药有限公司 罗替高汀的多晶型物
US8604242B2 (en) * 2008-10-13 2013-12-10 Interquim, S.A. Process for the preparation of optically active (S)-(−)-2-(N-propylamino)-5-methoxytetraline and (S)-(−)-2-(N-propylamino)-5-hydroxytetraline compounds
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
WO2011047350A2 (en) * 2009-10-16 2011-04-21 David Helton Emesis treatment
ME03053B (me) 2009-12-22 2018-10-20 Ucb Biopharma Sprl Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina
EP2697238B1 (en) * 2011-04-08 2019-03-20 Laurus Labs Limited Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
CN102634064B (zh) * 2012-04-10 2013-09-11 宁波长阳科技有限公司 一种含磷阻燃剂、阻燃聚酯薄膜及其制备方法
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2021206741A1 (en) * 2020-04-09 2021-10-14 Delahoussaye Kevin Modulating neurotransmitter concentration
DE102021213721A1 (de) * 2021-12-02 2023-06-07 Continental Reifen Deutschland Gmbh Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Farbstoff

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1017359A (en) * 1972-07-03 1977-09-13 Frederic P. Hauck Substituted cyclic polymethylene phenols
DE3062971D1 (en) 1979-09-14 1983-06-09 Sandoz Ag Derivatives of tetraline, their preparation and medicaments containing these compounds
US4465692A (en) 1982-01-03 1984-08-14 Nelson Research & Development Company Selective D-2 dopamine receptor agonist
US5177112A (en) 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
FR2563731B1 (fr) * 1984-05-07 1989-03-24 Nelson Res & Dev Composition therapeutique contenant de la 2-(n-phenylethyl-n-propylamino)-5-hydroxytetraline pour traiter la maladie de parkinson, pour stimuler selectivement les recepteurs de dopamine d-2 et procede de production d'une composition pharmaceutique utile au traitement de la maladie de parkinson
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
AU4312593A (en) 1992-05-18 1993-12-13 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
SE9301732D0 (sv) * 1993-05-18 1993-05-18 Haakan Wilhelm Wikstroem New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins
US5382596A (en) 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5442117A (en) 1993-12-13 1995-08-15 Albemarle Corporation Enantiomeric resolution
IT1292155B1 (it) 1997-06-13 1999-01-25 Zambon Spa Derivati naftotiazolonici attivi sul recettore dopaminergico d 3
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
AR026505A1 (es) * 1999-11-23 2003-02-12 Aderis Pharmaceuticals Inc Proceso mejorado para la preparacion de aminotetralinas sustituidas con nitrogeno
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
DE60100595T2 (de) 2001-05-08 2004-06-24 Lts Lohmann Therapie-Systeme Ag Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson
DK1256339T3 (da) 2001-05-08 2004-02-09 Sanol Arznei Schwarz Gmbh Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
US20030027793A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
US20060263419A1 (en) 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
EP1494664A2 (en) 2002-04-18 2005-01-12 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
US20040048779A1 (en) 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10220230A1 (de) 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US20060216336A1 (en) 2002-05-07 2006-09-28 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE60204229T2 (de) 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
CN101970422B (zh) 2007-11-28 2014-10-22 Ucb制药有限公司 罗替高汀的多晶型物
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
ME03053B (me) 2009-12-22 2018-10-20 Ucb Biopharma Sprl Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina

Also Published As

Publication number Publication date
IS8505A (is) 2006-06-12
SI1694318T1 (sl) 2007-08-31
PT1694318E (pt) 2007-05-31
CN1929829B (zh) 2010-12-15
US20140051768A1 (en) 2014-02-20
CY1106589T1 (el) 2012-01-25
EP1694318B1 (de) 2007-03-14
JP2007514674A (ja) 2007-06-07
DK1694318T3 (da) 2007-06-25
ES2282923T3 (es) 2007-10-16
PL1694318T3 (pl) 2007-07-31
AU2004298341B2 (en) 2011-03-10
HRP20070175T3 (en) 2007-06-30
ATE356621T1 (de) 2007-04-15
KR20060126500A (ko) 2006-12-07
HK1094421A1 (en) 2007-03-30
RS50536B (sr) 2010-05-07
WO2005058296A1 (de) 2005-06-30
AU2004298341A1 (en) 2005-06-30
US9108900B2 (en) 2015-08-18
US20070197480A1 (en) 2007-08-23
DE10359528A1 (de) 2005-07-28
KR101083568B1 (ko) 2011-11-14
DE502004003249D1 (en) 2007-04-26
US8609641B2 (en) 2013-12-17
CN1929829A (zh) 2007-03-14
EP1694318A1 (de) 2006-08-30
CA2547820C (en) 2013-02-19
JP5253737B2 (ja) 2013-07-31
MXPA06006696A (es) 2006-08-31
BRPI0417739A (pt) 2007-04-03
CA2547820A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
IS2533B (is) (S)-2-N-própýlamínó-5-hýdroxýetralín sem D3-gerandefni
UY28473A1 (es) Nuevos compuestos
BR0311494A (pt) Novos indóis substituìdos
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
MXPA05012680A (es) Indoles novedosos de 3-azufre sustituidos.
TW200728307A (en) Novel spirochromanone derivatives
IL173062A0 (en) Substituted 2-aminotetralin for the treatment of depression
DK1881967T3 (da) Substituerede benzo (D) isoaxol-3-yl-amin-forbindelser som analgetika
SE0202241D0 (sv) Novel Compounds
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
SI2150530T1 (sl) Substituirani sulfonamidni derivati
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
MXPA04006031A (es) Compuestos para el tratamiento de trastornos inflamatorios.
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
MX2010001303A (es) Compuestos terapeuticos.
MX2010001304A (es) Compuestos terapeuticos.
EA201070334A1 (ru) Пиперидиниламинотиено[2,3-d]пиримидиновые соединения для лечения фиброза
MX2008002073A (es) Compuestos para el tratamiento de trastornos inflamatorios.
DE602007008947D1 (en) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3-modulatoren